New inhaled powder tested for scarred lungs

NCT ID NCT07344558

Recruiting now Disease control Sponsor: Mannkind Corporation Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing the safety and how the body processes a new inhaled powder version of a drug called nintedanib in people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. The trial will enroll about 24 patients to see if inhaling the drug is safe and well-tolerated compared to a placebo. The main goal is to find the right dose and check for side effects like breathing problems after using the inhaler.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Low Country Research
RECRUITING

Charleston, South Carolina, 29406, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Metroplex Pulmomary & Sleep Center
NOT_YET_RECRUITING

McKinney, Texas, 75069, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Palmtree Clinical Research
RECRUITING

Palm Springs, California, 92262, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Southeastern Research Center
RECRUITING

Winston-Salem, North Carolina, 27103, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
VALDI
NOT_YET_RECRUITING

Fresno, California, 93720, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

IDIOPATHIC PULMONARY FIBROSIS (IPF)